Reality Check on Crohn's Disease
Market access for Crohn's disease treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, almost 57% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In July 2020, the FDA approved Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd.’s Hulio (adalimumab-fkjp) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis
- Key Findings: New-to-market products should expect stiff competition due to the number of originator biologics and biosimilars available and in the pipeline. Also, with most products demonstrating similar clinical efficacy, with the exception of anti-tumor necrosis factor agents, which stand out as preferred biologics in clinical guidelines, patient cost will be a determining factor for prescribers; therefore, contracting remains extremely important for market success
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.